UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other jur ...

2 In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this presentation also contains the following non-GAAP financial measures: non-GAAP R&D expense, non-GAAP SG&A expense, and non-GAAP net income and net income per share. When preparing the non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Conference Call February 6, 2023 8:00 AM ET Company Participants Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development and Strategy Officer Todd Tushla - VP of IR Conference Call Participants Paul Matteis - Stifel Neena Bitritto-Garg - Citi Tazeen Ahmad - Bank of America Brian Skorney - Baird Phil Nadeau - Cowen & Company Chris Shibutani - Goldman ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Todd Tushla - VP of IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development & Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Paul Matteis - Stifel Phil Nadeau - Cowen & Company Neena Bitritto-Garg - Citi Anupam Rama - JPMorgan Brian Abrahams - RBC Capit ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Phil Nadeau - Cowen & Company Leonid Timashev - RBC Capital Markets Paul Matteis - Stifel T ...

| --- | --- | --- | --- | --- | |---------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Advancing | | | | | | Life-Changing Discoveries in Neuroscience | | | | | | Q1 2022 Corporate Presentation | | | | | | May 4, 2022 Nasdaq: NBIX | | | | | | | | | | | Safe Harbor Statement and Non-GAAP Financial Measures 2 In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncert ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO & Director Matthew Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company Brian Skorney - Robert W. Baird & Co. Carter Gould - Barclays Bank Neena Bitritto-Garg - Citigroup Tazeen Ah ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2021 Results Conference Call February 11, 2022 8:00 AM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer and Director Matt Abernethy - Chief Financial Officer Dr. Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Phil Nadeau - Cowen Paul Matteis - Stifel Tazeen Ahmad - Bank of America B ...

J.P. Morgan Healthcare Conference January 2022 Safe Harbor Statement 2 In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; our financial and operating performance, including ...